From the Program on Health, Work and Productivity (Drs Lerner, Chang, and Rogers), Institute for Clinical Research and Health Policy Studies (Drs Lerner, Chang, and Rogers), Tufts Medical Center, Tufts University School of Medicine, Boston, MA; Sackler Graduate School of Biomedical Sciences (Drs Lerner, Chang, and Rogers), Boston, MA; and Janssen Scientific Affairs, LLC (Mr Benson and Drs Chow, Kim, and Biondi).
J Occup Environ Med. 2012 Aug;54(8):933-8. doi: 10.1097/JOM.0b013e31825f31a1.
: To determine the impact of tapentadol extended release (ER) versus placebo or oxycodone controlled release (CR) on the work productivity of adults with chronic moderate to severe knee osteoarthritis pain.
: Using clinical trial data on pain outcomes, a validated methodology imputed treatment group differences in at-work productivity and associated differences in productivity costs (assuming a $100,000 annual salary per participant).
: Imputed improvements in at-work productivity were significantly greater for tapentadol ER compared with either placebo (mean, 1.96% vs 1.51%; P = 0.001) or oxycodone CR (mean, 1.96% vs 1.40%; P < 0.001). Mean net savings per participant were $450 (P < 0.01) for tapentadol ER versus placebo and $560 (P = 0.001) for tapentadol ER versus oxycodone CR.
: Effective osteoarthritis pain treatment also may help employees to function better at work and reduce their employers' productivity costs.
确定盐酸他喷他多缓释片（ER）与安慰剂或盐酸羟考酮控释片（CR）相比，对慢性中重度膝骨关节炎疼痛的成年患者的工作生产力的影响。
使用疼痛结局临床试验数据，采用一种经过验证的方法，推断治疗组在工作生产力方面的差异，以及由此产生的生产力成本差异（假设每位参与者的年薪为 10 万美元）。
与安慰剂（平均提高 1.51%；P=0.001）或盐酸羟考酮控释片（平均提高 1.40%；P<0.001）相比，盐酸他喷他多 ER 可显著提高工作中的生产力。与安慰剂相比，每位参与者的平均净节省额为 450 美元（P<0.01），与盐酸羟考酮控释片相比，节省额为 560 美元（P=0.001）。
有效的骨关节炎疼痛治疗还可能帮助员工更好地工作，并降低雇主的生产力成本。
